Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose vs Routine Dose Icotinib in Pretreated NSCLC
NCT02027090Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02027090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02027090.